pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
Argenx clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Argenx projects
2 ClinicalTrials.gov programs sponsored by Argenx.
Argenx has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
Frequently asked questions
How many clinical projects does Argenx have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.